Hormone Therapy Breast Cancer Success Rate 2025
Success Rate of Hormone Therapy for Breast Cancer: What Patients need to Know in 2025
This article from OncoDaily discusses the success rates of hormone therapy in treating both early-stage and metastatic/advanced HR+ (hormone receptor-positive) breast cancer.
Key Takeaways:
* Early-stage Breast Cancer:
* Hormone therapy (like Tamoxifen or aromatase inhibitors) reduces the risk of cancer recurrence by 40-50% and mortality by 30-40% after surgery.
* Tamoxifen cuts the 15-year risk of recurrence by about one-third.
* Aromatase inhibitors offer an additional 30% reduction in recurrence risk compared to Tamoxifen in postmenopausal women.
* 85-90% of patients remain disease-free five years after completing surgery and hormone therapy (depending on tumor characteristics).
* Metastatic/Advanced Breast Cancer:
* Hormone therapy is the cornerstone of first-line treatment, often combined with targeted therapies (CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors).
* Hormone therapy alone achieves response rates of 30-40% with PFS of 8-14 months.
* Combining hormone therapy with a CDK4/6 inhibitor substantially improves outcomes, doubling PFS to 24-30 months and extending overall survival to over 60 months.
* Recurrence & Resistance:
* Resistance to hormone therapy can develop, linked to genetic mutations (ESR1, PIK3CA, AKT1) or activation of choice growth pathways.
* Research is ongoing to overcome resistance.
Links to further reading on oncodaily:
The article cites several studies:
* Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 2019
* Pan et al., Lancet, 2017
* Johnston et al., J Clin Oncol, 2021
* MONALEESA-2, PALOMA-2, and MONARCH-3 trials.